Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of JAB-21822 in Combination With JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

NCT05288205 is registered in ClinicalTrials.gov with Allist Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05288205
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05288205 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of JAB-21822 in Combination With JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
Lead sponsor
Allist Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 14, 2022
Completion date
March 31, 2027
Enrollment
240 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, kras p.g12c, non-small cell lung cancer, pancreatic ductal carcinoma